Adolescent vaccine co-administration and coverage in New York City: 2007-2013.
OBJECTIVE
To investigate adolescent vaccination in New York City, we assessed tetanus, diphtheria, and acellular pertussis (Tdap), meningococcal conjugate (MCV4), and human papillomavirus (HPV) vaccine uptake, vaccine co-administration, and catch-up coverage over time.


METHODS
We analyzed data from the Citywide Immunization Registry, a population-based immunization information system, to measure vaccine uptake and co-administration, defined as a Tdap vaccination visit where MCV4 or HPV vaccine was co-administered, among 11-year-olds. Catch-up vaccinations were evaluated through 2013 for adolescents born 1996 to 2000, by birth cohort. HPV vaccination among boys included data from 2010 to 2013.


RESULTS
Adolescent vaccine administration was greatest during the back-to-school months of August to October and was highest for Tdap. Although MCV4 uptake improved over the study years, HPV vaccine uptake among girls stagnated; boys achieved similar uptake of HPV vaccine by 2012. By 2013, 65.4% had MCV4 co-administered with Tdap vaccine, whereas 28.4% of girls and 25.9% of boys had their first dose of HPV vaccine co-administered. By age 17, Tdap and MCV4 vaccination coverage increased to 97.5% and 92.8%, respectively, whereas ≥1-dose and 3-dose HPV vaccination coverage were, respectively, 77.5% and 53.1% for girls and 49.3% and 21.6% for boys. Age-specific vaccination coverage increased with each successive birth cohort (P < .001).


CONCLUSIONS
From 2007 to 2013, there were greater improvements in Tdap and MCV4 vaccination than HPV vaccination, for which co-administration with Tdap vaccine and coverage through adolescence remained lower. Parent and provider outreach efforts should promote timely HPV vaccination for all adolescents and vaccine co-administration.
Bureau of Immunization, New York City Department of Health and Mental Hygiene, New York, New York; msull@health.nyc.gov.
Monica
M
Sull
Bureau of Immunization, New York City Department of Health and Mental Hygiene, New York, New York; Center for Health Statistics, Washington Department of Health.
Joanna
J
Eavey
Bureau of Immunization, New York City Department of Health and Mental Hygiene, New York, New York;
Vikki
V
Papadouka
Bureau of Immunization, New York City Department of Health and Mental Hygiene, New York, New York; Department of Health Behavior and Health Education, University of Michigan, Ann Arbor, Michigan;
Rebecca
R
Mandell
Bureau of Immunization, New York City Department of Health and Mental Hygiene, New York, New York; Atlantic Management Center, Inc., Columbus, Ohio; and.
Michael A
MA
Hansen
Bureau of Immunization, New York City Department of Health and Mental Hygiene, New York, New York; Immunization Services Division/National Center for Immunization and Respiratory Diseases/Centers for Disease Control & Prevention, Atlanta, Georgia.
Jane R
JR
Zucker
D000293:Adolescent; D015331:Cohort Studies; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000639:trends; D008297:Male; D032541:Mass Vaccination / Q000639:trends*; D022401:Meningococcal Vaccines / Q000008:administration & dosage; D009519:New York City; D053918:Papillomavirus Vaccines / Q000008:administration & dosage; D014505:Urban Population; D017778:Vaccines, Combined / Q000008:administration & dosage*
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D022401:Meningococcal Vaccines; D053918:Papillomavirus Vaccines; D017778:Vaccines, Combined; C410218:serogroup C meningococcal conjugate vaccine
HPV vaccine; MCV4; Tdap; adolescent immunization; co-administration